Leukadherin-1
产品说明书
 |
同义名 : | - |
| CAS号 : | 344897-95-6 | |
| 货号 : | A292458 | |
| 分子式 : | C22H15NO4S2 | |
| 纯度 : | 99% | |
| 分子量 : | 421.49 | |
| MDL号 : | MFCD01151276 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The β2 integrin CD11b/CD18 (also known as Mac-1, aMb2, and CR3)，expressed primarily in the cells of the innate immune system，is a key adhesion receptor that mediates leukocyte migration and immune functions. ICAM-1 (CD54)，a member of the immunoglobulin family，is expressed on the surface of vascular endothelial cells and mediates migration and tissue recruitment of leukocytes from circulation. Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1. Daily LA1 intraperitoneal treatment at 2.5 mg/kg reduced interstitial leukocyte infiltration in the kidney allograft, reduced neointimal hyperplasia and glomerular damage, and prolonged graft survival from 48.5% (CsA only) to 100% (CsA and LA1) on day 60[3]. LA1 pre-treatment at 7.5 mM reduced secretion of IFN–γ, TNF and MIP-1β by monokine-stimulated Natural Killer (NK) cells which was associated with a decrease in pSTAT5 following IL-12+IL-15 stimulation (P<0.02) and increased IL-10 secretion following IL-12+IL-18 stimulation (P<0.001). Also, LA1 pre-treatment reduced secretion of IL-1β, IL-6 and TNF by Toll-like receptor (TLR) 2 and TLR7/8–stimulated monocytes[4]. | ||
| 作用机制 | Leukadherin-1 enhances binding of CD11b/CD18 to ICAM-1 via the formation of long membrane tethers. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.37mL 0.47mL 0.24mL |
11.86mL 2.37mL 1.19mL |
23.73mL 4.75mL 2.37mL |
| 参考文献 |
|---|